Live- In Person Dayton Meeting

1.0 NCPD Credit
Click Here to complete the pre-assessment

This CE activity is intended for oncology nurses and NPs who provide care for individuals with CLL and SLL.

After completing this CE activity, the participant should be better able to:

  • Evaluate emerging data regarding the mechanism of action and long-term safety and efficacy of recommended agents and combinations, including those of fixed duration and mutation-based regimens
  • Identify the most common and serious adverse events (AEs) that emerge during treatment with targeted therapies and combination regimens including negative outcomes associated with mutations in black patients
  • Engage patients of all backgrounds and ethnicities in discussion of the risks of AEs relative to treatment outcomes

Joint Accreditation with Commendation Logo In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hours and 1.0 contact hours in the area of pharmacology.

Supporter

This CE activity is supported through an educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Pre-Assessment

Please enable JavaScript in your browser to complete this form.
What is the most diagnosed leukemia in the US?
On average, what percentage of patients with CLL/SLL need treatment upon diagnosis?
What is the least common upfront treatment option for CLL/SLL?
A 70-year-old patient with CLL is very fearful about COVID-19 and would prefer to avoid time in the hospital; however, says she would be okay with it for short periods, if necessary. Which of these regimens would you recommend?
A 67-year-old patient with CLL and a TP53 mutation prefers a fixed-duration regimen. Which of the following would you recommend?
A young, fit, patient with CLL with high tumor burden is going to start on a fixed-duration ibrutinib + venetoclax regimen. What AE will you be most concerned about in the beginning of therapy?
A patient with CLL and TP53 mutation is starting acalabrutinib and obinutuzumab in the next few days. Which of these AEs would you counsel him to monitor for?
A patient newly diagnosed with CLL is feeling unsure about whether to pick a fixed- or continuous-duration regimen. She wants your advice. How would you approach her in a way that she feels comfortable with the decision?
When trying to build trust with a patient, what is one of the most important things you can do?
Go to Event Site
Scroll to Top